Close Menu
Invest Insider News
    Facebook X (Twitter) Instagram
    Sunday, November 22
    Facebook X (Twitter) Instagram Pinterest Vimeo
    Invest Insider News
    • Home
    • Bitcoin
    • Commodities
    • Finance
    • Investing
    • Property
    • Stock Market
    • Utilities
    Invest Insider News
    Home»Stock Market»Cipla share price: HSBC expects 13% upside for the stock post Q1 results on firm US prospects.
    Stock Market

    Cipla share price: HSBC expects 13% upside for the stock post Q1 results on firm US prospects.

    July 29, 20243 Mins Read


    Stock Market today: Cipla share price that has gained more than 24% year to date is trading near 52 week highs it scaled on Friday. Cipla had reported strong Q1 performance with net profit rising 17% YoY largely helped by improved operating performance as reported Ebitda grew 14% though revenue grew t a slower pace of 7% year-on-year.

    While India Business contributing more than 40% to overall grew 5%, The strong US sales growth lifted the show.

    Get Quick Cash in Minutes!

    Best Personal Loan at Lowest Interest Rates

    Instant Apply

    Robust US performance- Cipla’s US sales at $250 million contributing 31.2% to the first quarter revenue) grew 12.6% y-o-y and10.6% sequentially. The same was helped by market share gains for key launches like hormone drug lanreotide, respiratory inhaler albuterol generics as well as well supported by higher generic Revlimid sales .

    Cipla further has indicates that it should sustain US sales of $235-240 mullion in remaining quarters of FY25, which remains a key positive

    Analysts at HSBC Securities and Capital Markets (India) Pvt Ltd believe lanreotide generic has plenty of room to grow as the brand still holds 78% share of the overall lanreotide market. Further there are three more peptides launches planned by Cipla over the next 12 months starting in 2HFY25. HSBC analysts say that the traction in existing products and peptide launches should help Cipla to sustain US sales growth in FY25 and beyond. This should also ease concerns regarding delays in the launch of respiratory products, as generics of Abraxane and generic Advair which remain delayed due to pending plant clearances by USFDA.

    For the domestic business growth , Cipla has highlighted that India Branded Prescription Business grew at a healthy rate of 10% yoy. it was the softness in Trade Generics Business owing to distribution model change that led to softer overall growth for Cipla Business.



    HSBC continues to like Cipla’s healthy outlook in key segments (India, South Africa, the US), delivery on cost efficiencies, and prudent capital allocation. Notable HSBC says that the pipeline products – inhalers and peptides should provide comfort for the growth outlook of US sales despite a high base. Their target price for Cipla revised upwards to ₹1,775 (from ₹1,680) indicates more than 13% uspide for Cipla share price.



    Disclaimer: The views and recommendations made above are those of individual analysts or broking companies, and not of Mint. We advise investors to check with certified experts before taking any investment decisions




    Topics You May Be Interested In



    Source link

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
    Previous ArticleJohnvents Industries DMCC Expands Global Reach with Launch of Uganda Operations, Targets Strategic Markets for Growth
    Next Article Bitcoin at Point of Cycle Right Before Parabolic Expansion, According to Crypto Analyst

    Related Posts

    Stock Market

    Auto stocks lead European shares lower amid US-China trade standoff

    November 21, 2026
    Stock Market

    Investors Put $45.7 Billion Into U.S. Stock Funds Right Before the Stock Market Tanked

    November 21, 2026
    Stock Market

    Stock market drop: What’s behind this correction?

    November 21, 2026
    Leave A Reply Cancel Reply

    Top Posts

    How is the UK Commercial Property Market Performing?

    December 31, 2000

    How much are they in different states across the US?

    December 31, 2000

    A Guide To Becoming A Property Developer

    December 31, 2000
    Stay In Touch
    • Facebook
    • YouTube
    • TikTok
    • WhatsApp
    • Twitter
    • Instagram
    Latest Reviews
    Property

    Why Property Insurance is Essential for Financial Security

    December 17, 2025
    Stock Market

    Market Close: Sensex slumps 1,000 points, Nifty ends below 23,900 on escalating West Asia tensions | Markets News

    April 23, 2026
    Investing

    AMD stock has ‘over-corrected’: Barclays By Investing.com

    July 29, 2024
    What's Hot

    Cyber cover lags furthest behind in UK property, GlobalData finds

    September 21, 2026

    Bitcoin’s silent exodus hits crypto as long-time buyers cash out

    December 18, 2025

    Upcoming earnings ‘a clearing event’ for CrowdStrike By Investing.com

    August 22, 2024
    Most Popular

    Business News Today: Stock and Share Market News, Economy and Finance News, Sensex, Nifty, Global Market, NSE, BSE Live IPO News

    March 21, 2026

    Apollo, Morpho and the Shift to Open Financial Networks

    March 20, 2026

    Structured Finance Explained: Benefits and Real-World Examples

    August 25, 2025
    Editor's Picks

    Bitcoin stabilises above $70,000 amid intensity of Iran conflict escalates

    March 4, 2026

    Hackers Stole $100 Million in Bitcoin—Here’s How

    August 4, 2026

    FTSE 100 scores best year since 2009 and outperforms Wall Street

    December 31, 2025
    Facebook X (Twitter) Instagram Pinterest Vimeo
    • Get In Touch
    • Privacy Policy
    • Terms and Conditions
    © 2026 Invest Insider News

    Type above and press Enter to search. Press Esc to cancel.